Mover to Watch: Cara Therapeutics (CARA)

Rebecca Barbier
Julho 7, 2017

Cara Therapeutics (NASDAQ:CARA) has a market cap of $811.58 Million and the number of outstanding shares have been calculated 53.89 Million. (NASDAQ:CARA) from a strong-buy rating to a buy rating in a report issued on Wednesday, June 21st. The brokerage now has $21.73 price objective on the biopharmaceutical company's stock.

Cara Therapeutics Inc. was covered by a number of analysts recently, 2 rated the stock as Buy, 1 rated Hold, 0 rated sell and 0 gave an Underperform. Janney Montgomery Scott cut shares of Cara Therapeutics from a buy rating to a neutral rating and lowered their price target for the stock from $22.00 to $21.00 in a research report on Friday, June 30th.

Cara Therapeutics, Inc. (NASDAQ:CARA) share price decreased in the last trading session with a previous 52-week high of $28.50. HC Wainwright reaffirmed a buy rating and set a $30.00 price target on shares of Cara Therapeutics in a research report on Thursday, June 22nd. Finally, Vetr raised Cara Therapeutics from a hold rating to a buy rating and set a $18.44 target price for the company in a report on Wednesday, April 5th. Cara Therapeutics has a consensus rating of "Buy" and a consensus target price of $25.68. Ameriprise Financial owns 0% invested in Cara Therapeutics Inc (NASDAQ:CARA) for 104,343 shares.

Cara Therapeutics (NASDAQ:CARA) as of recent trade, has shown weekly downbeat performance of -44.12% which was maintained at -12.85% in 1-month period. The company has market cap of $471.03 million. The level of 50 represents neutral market momentum and corresponds with the center line in other oscillators such as MACD (Moving Average Convergence/Divergence). Cara Therapeutics Inc (NASDAQ:CARA) has risen 206.00% since July 6, 2016 and is uptrending.

Federation Internationale de Football Association ban takes toll on Uganda Cranes internationals in Sudan
The FIFA ban means that all Sudan clubs are no longer entitled to take part in global competitions as per article 13 of the FIFA statutes.

Impinj, Inc. (PI) surprised the stock market in its last reported earnings when it earned $0.11 a piece versus the consensus-estimated $0.09. The company had revenue of $0.91 million for the quarter, compared to the consensus estimate of $0.11 million. The firm's quarterly revenue was up 12900.0% compared to the same quarter past year. On average, equities analysts expect that Cara Therapeutics will post ($2.44) earnings per share for the current fiscal year.

WARNING: This story was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another website, it was stolen and republished in violation of United States & global copyright and trademark law. The original version of this story can be accessed at https://www.chaffeybreeze.com/2017/07/07/cara-therapeutics-inc-cara-rating-reiterated-by-stifel-nicolaus-updated.html.

In related news, Director Dean Slagel sold 250,000 shares of the stock in a transaction on Thursday, June 29th. FISHER JOHN B had sold 9,191 shares worth $243,414 on Monday, March 6. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The same analysts are predicting that the company shares will trade to $26.57 within the next 12-18 months.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CARA. Tiedemann Wealth Management LLC raised its stake in Cara Therapeutics by 7.5% in the first quarter. Private Advisor Group LLC raised its stake in Cara Therapeutics by 120.5% in the first quarter. The Cam Group Holding A holds 319,820 shares with $2.97M value, up from 268,000 last quarter. Creative Planning now owns 14,340 shares of the biopharmaceutical company's stock valued at $264,000 after buying an additional 1,215 shares in the last quarter. Cambridge Investment Research Advisors Inc. now owns 11,824 shares of the biopharmaceutical company's stock worth $217,000 after buying an additional 60 shares during the last quarter. Dimensional Fund Advisors LP now owns 229,626 shares of the biopharmaceutical company's stock valued at $2,133,000 after buying an additional 62,518 shares in the last quarter.

Outros relatórios LazerEsportes

Discuta este artigo

SIGA O NOSSO JORNAL